BioSpace News Archive

Lyell Immunopharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL132.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that six abstracts highlighting the clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium.

Azenta, Inc. (Nasdaq: AZTA) will announce fiscal 2022 first quarter earnings which ended on December 31, 2021 on Tuesday, February 8, 2022 after the market closes.

9 Meters Biopharma, Inc. announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 17/239,056 is allowed.

dNovo Inc., a Silicon Valley company developing a cure for hair loss by generating personalized hair stem cells, emerged from stealth and announced $2.7M in seed funding from Y Combinator, Felicis Ventures, Soma Capital, Yintai Investment Company LLC, and others.

Spruce Biosciences, Inc. today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies.

PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of Pathology Consultants, a leading provider of pathology services based in Greenville, S.C.

Fluidigm Corporation (NASDAQ:FLDM), today announced that its Board of Directors has unanimously approved a $250 million investment by leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”).

Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics.

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed an International Marketing, Sales and Clinical Management Agreement with Medtech Solutions Group (“MTSG”), a leader in the commercialization of healthcare technologies.